The study provides additional scientific support for AKIR001 and reinforces the preclinical foundation of our CD44v6-targeted strategy in molecular radiotherapy. The recognition by SNMMI also reflects the growing interest in targeted radiopharmaceuticals and CD44v6 as a therapeutic target

Advancing to cohort 3 marks an important step in our clinical development program. The results support further evaluation of dose levels, and the next stage will be central to further defining dosing parameters and treatment characteristics ahead of future stages of development.

The decision to proceed to cohort 3 follows a thorough safety evaluation. We look forward to continuing the study and collecting additional clinical data.

We are pleased to see the study recognized both as best basic investigation and as overall featured article in JNM. It is a strong recognition of the preclinical work behind AKIR001 and adds further weight as the program advances in clinical development.

Completing cohort 2a marks solid and steady progress in our dose-escalation strategy. The consistency of the safety profile together with encouraging tumor uptake provides confidence as the study advances into the next step of the dose-escalation stage and confirms that development remains on track. Protein-dose optimization is central to preparing for subsequent stages of evaluation.

These results bring together years of systematic development around our CD44v6 platform—spanning antibody engineering, dosimetry, in vivo studies and safety assessments. Having the work peer-reviewed adds an extra layer of confidence as the drug is now being evaluated in patients at Karolinska University Hospital. For us, it reaffirms that we are advancing on a solid and well-supported scientific foundation.

We’re honored to once again be part of the EANM Congress. It’s encouraging to see how the scientific foundation of our CD44v6 platform continues to grow—while our clinical candidate moves through its first human trial. These efforts reflect our long-standing commitment to collaboration, innovation, and patient impact.

Completing the first cohort marks an important milestone for AKIR001. Our goal is to develop a treatment that reaches tumors with high selectivity and has a favorable safety profile. These initial clinical data support the next step in development.

The completion of cohort 1 without unexpected side effects represents an important step forward. The results suggest that the drug is well tolerated at the doses tested so far, and we are pleased to proceed as planned.

The launch of the clinical trial with AKIR001 marks the beginning of a new chapter for Akiram. Our vision has always been to develop a treatment that can offer new opportunities for patients with difficult-to-treat cancers, where treatment options are often limited. Seeing our drug candidate now being evaluated in collaboration with Karolinska University Hospital—one of Europe’s leading cancer centers—is a major milestone and a strong motivator for our continued work.

The enrollment of the first patient means that we have now initiated dose escalation and systematic evaluation of AKIR001’s safety and potential. This is an important first step in understanding how the drug behaves clinically and the potential role a CD44v6-targeted therapy could play in tumor types where treatment options today remain limited.

By separating the targeting step from the therapeutic phase, we open up new possibilities for designing more precise and effective cancer treatments, This innovative therapeutic modality builds on our CD44v6 platform and represents an opportunity to expand our pipeline beyond beta-emitting radiotherapies.

Presenting at the TRP Summit is an exciting opportunity to share the progress of 177Lu-AKIR001 with the international radiopharmaceutical community. The therapy holds the potential to become a first-in-class treatment for multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. With clinical trials set to begin at Karolinska University Hospital in Sweden in early 2025, we are thrilled to contribute to discussions shaping the future of targeted cancer therapies.

The start of the Phase 1 clinical trial is a significant milestone for Akiram and an important step forward in molecular radiation therapy. We are excited to collaborate with Karolinska University Hospital and are confident in AKIR001's potential to improve treatment outcomes for patients.

177Lu-AKIR001 has the potential to transform how we treat hard-to-treat tumors and could represent a major advancement in precision medicine.

177Lu-AKIR001 has shown great preclinical potential to transform the treatment of CD44v6-expressing tumors. We are looking forward to starting phase 1 studies later this fall, with the goal of offering new, targeted treatment options for patients with hard-to-treat cancers. The selection of our presentation as one of the top-rated talks is a clear recognition of the promising research, and we are excited to share the results with the international scientific community.

With this agreement and the GMP production of the affinity carrier in place, we have everything needed to apply for a first-in-human clinical study in 2024. We are very excited and strongly motivated to progress this important project in close collaboration with our clinical colleagues at Karolinska University Hospital.

It is with great pleasure that we welcome Anna Törner and Peder Walberg to Akiram's board. We are facing important developmental steps, and their investment and commitment to the company are strong indications of confidence in our strategic direction and our ability to realize our goals in cancer treatment.

The grant is a testament to our commitment to pioneering cancer treatments. This generous support from the Erling-Persson Foundation allows us to advance our mission, offering hope and potential solutions to individuals suffering from incurable cancers.

We are honored to have the opportunity to present at the Annual EANM Congress. We look forward to sharing promising data about our drug candidate, which we believe holds the potential to significantly impact patient care and radiopharmaceutical sciences in the future. Participating in this global conversation that's shaping the future of Nuclear Medicine is genuinely exciting.

We would like to thank Sciety and all those who have participated in this successful issue for the great confidence in Akiram and our drug candidate. We now have the means to continue our work at full speed and take the next important steps on our exciting journey. We are very eager to continue the development of our drug candidate and to initiate phase I clinical studies.